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Abstract
The binding of human complement inhibitors to vaccine antigens in vivo could diminish their immunogenicity. A
meningococcal ligand for the complement down-regulator, factor H (fH), is fH-binding protein (fHbp), which is specific for
human fH. Vaccines containing recombinant fHbp or native outer membrane vesicles (NOMV) from mutant strains with
over-expressed fHbp are in clinical development. In a previous study in transgenic mice, the presence of human fH impaired
the immunogenicity of a recombinant fHbp vaccine. In the present study, we prepared two NOMV vaccines from mutant
group B strains with over-expressed wild-type fHbp or an R41S mutant fHbp with no detectable fH binding. In wild-type
mice in which mouse fH did not bind to fHbp in either vaccine, the NOMV vaccine with wild-type fHbp elicited 2-fold higher
serum IgG anti-fHbp titers (P=0.001) and 4-fold higher complement-mediated bactericidal titers against a PorA-
heterologous strain than the NOMV with the mutant fHbp (P=0.003). By adsorption, the bactericidal antibodies were shown
to be directed at fHbp. In transgenic mice in which human fH bound to the wild-type fHbp but not to the R41S fHbp, the
NOMV vaccine with the mutant fHbp elicited 5-fold higher serum IgG anti-fHbp titers (P=0.002), and 19-fold higher
bactericidal titers than the NOMV vaccine with wild-type fHbp (P=0.001). Thus, in mice that differed only by the presence of
human fH, the respective results with the two vaccines were opposite. The enhanced bactericidal activity elicited by the
mutant fHbp vaccine in the presence of human fH far outweighed the loss of immunogenicity of the mutant protein in wild-
type animals. Engineering fHbp not to bind to its cognate complement inhibitor, therefore, may increase vaccine
immunogenicity in humans.
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Introduction
Neisseria meningitidis causes sepsis and meningitis with relatively
high rates of fatalities or severe permanent sequelae [1,2]. Li-
censed quadrivalent polysaccharide-protein conjugate vaccines are
available against four capsular groups: A, C, W135 and Y. De-
velopment of conjugate vaccines against group B strains, however,
has been hampered by cross-reactivity of the group B polysac-
charide with host molecules [3,4], and safety concerns about the
potential to elicit auto-reactive antibodies. Development of a
vaccine against group B strains is important since these strains are
responsible for about one-third of cases of meningococcal disease
in the U.S. [1] and up to 90% in some European countries [5].
Several non-capsular antigen-based vaccines are being developed
against group B meningococci (reviewed in [6,7]). One of the most
promising antigens is factor H-binding protein (fHbp) [8,9]. Vaccines
containing recombinant fHbp [10–12] or native outer membrane
vesicles (NOMV) from mutant meningococcal strains with over-
expressed fHbp [13,14] are being tested in humans. After clinical
testing had started, fHbp was discovered to bind complement factor
H (fH) [15]. Further, binding was found to be specific for human fH
[16]. Binding of a host protein to a vaccine antigen could in theory
decrease immunogenicity by covering important epitopes or
decreasing uptake, processing or presentation of the antigen. Also,
theimplicationsofbindingahumancomplementproteintoavaccine
antigen with respect to its effect on immunogenicity or the potential
safety concern of eliciting auto-antibodies had not been considered at
the time of starting the clinical trials with these vaccines.
Using transgenic mice, we recently reported that the presence
of human fH impaired immunogenicity of a recombinant fHbp
vaccine that bound human fH [17]. In that study we also described
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serine (R41S) abrogated binding of fH to the fHbp vaccine. Serum
bactericidal antibody responses of human fH transgenic mice im-
munized with the recombinant R41S mutant fHbp vaccine were
higher than those of mice immunized with the recombinant wild-
type fHbp vaccine that bound fH.
In wild-type mice, NOMV vaccines from mutants with gene-
tically attenuated endotoxin and over-expressed fHbp elicited
high titers of serum anti-fHbp antibodies, which had broader (i.e.
in terms of strain coverage) complement-mediated bactericidal
activity than anti-fHbp antibodies elicited by recombinant fHbp
vaccines [18–23]. Thus, NOMV vaccines from mutants with in-
creased fHbp expression appear to be a promising approach to
elicit broad protective immunity against meningococcal group B
strains. An important limitation of these studies was that they
were done in wild-type mice whose mouse fH did not bind to the
fHbp antigens. Therefore, the studies did not assess the possible
effect of human fH on vaccine immunogenicity. In the present
study we used human fH transgenic mice to investigate the
immunogenicity of NOMV vaccines containing wild-type fHbp,
or a mutant fHbp antigen that had no detectable binding of
human fH.
Materials and Methods
Ethics statement
Vaccine immunogenicity was evaluated in mice in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocols were approved by the Institutional Animal
Care and Use Committees at Children’s Hospital Oakland Re-
search Institute and the University of Massachusetts Medical
School. Blood collection was performed under anesthesia, and all
efforts were made to minimize suffering. The human complement
source for measuring serum bactericidal activity was serum from
an adult who participated in a protocol that was approved by
Institutional Review Board (IRB) of Children’s Hospital Oakland
Research Institute. Written informed consent was obtained from
the subject.
Construction of vaccine strains
The NOMV vaccines were prepared from mutants of group B
vaccine strain H44/76 (Table 1). The parent strain was isolated
from a patient with invasive disease during an epidemic in
Norway, and was used to prepare a detergent-extracted OMV
vaccine [24,25]. The wild-type H44/76 strain naturally expresses
a high level of fHbp amino acid sequence variant ID 1 as classified
in the public database of fHbp variants (http://pubmlst.org/
neisseria/fHbp/). To attenuate endotoxin [26], the LpxL1 gene
was deleted as previously described [23], which resulted in penta-
acylated instead of hexa-acylated lipo-oligosaccharide (LOS)
[26,27]. The resulting mutant strain (H44/76DLpxL1, Table 1)
was then transformed with one of three plasmids: pBSDfHbp::erm
[8], pBS-erm-fHbp wild-type (WT), or pBS-erm-fHbp R41S. The
pBS-erm-fHbp WT plasmid was constructed by subcloning a
cassette containing a modified PorA promoter, in which the po-
lyguanine tract between the 235 and 210 sites was replaced with
the corresponding sequence from the NadA gene, followed by the
fHbp ID 1 gene, downstream of the erm cassette of pBSDf-
Hbp::erm. The R41S substitution was introduced into WT fHbp
as described previously [17]. To increase over-expression of fHbp,
a second copy of the cassette containing the modified PorA pro-
moter and the WT fHbp gene was subcloned into pFP12 using the
SphI and StuI restriction sites as described previously [28]. The
modified plasmid was used to transform the strain with WT fHbp
Author Summary
Vaccines containing factor H-binding protein (fHbp) are
being developed for protection against bacterial meningi-
tis and sepsis caused by meningococci. The antigen was
identified from genomic sequences and only later found to
bind a human complement protein, factor H (fH), but not
fH from non-human species. In previous studies, native
outer membrane vesicle (NOMV) vaccines from mutants
with over-expressed fHbp elicited broadly protective
serum antibodies in mice whose fH did not bind to fHbp
in the vaccine. In this study, the authors immunized
transgenic mice and showed that the presence of human
fH decreased serum bactericidal antibody responses to a
NOMV vaccine with fHbp that bound human fH. In
contrast, a NOMV vaccine containing fHbp with a single
amino acid substitution that eliminated fH binding elicited
nearly twenty-fold higher protective antibody responses.
Thus, a simple change in a vaccine antigen to eliminate
binding to a host protein can increase immunogenicity.
Table 1. Characteristics of strains used in this study.
Strain
PorA VR
Type
a
fHbp
ID
b
fHbp vari-
ant group
c Purpose
Wild-type (WT) H44/76 7,16 1 1 Parental vaccine strain with naturally high expression of fHbp
H44/76DLpxL1 7,16 1 1 Mutant with attenuated endotoxin, which was used to engineer
second fHbp mutants
H44/76DLpxL1DfHbp 7,16 None None Preparation of control NOMV that lacks fHbp
H44/76DLpxL1 with over-expressed WT fHbp 7,16 1 1 Preparation of NOMV with over-expressed fHbp that binds human fH
H44/76DLpxL1 with over-expressed R41S
mutant fHbp
7,16 R41S mutant
of ID 1
1 Preparation of NOMV with over-expressed mutant fHbp that does
not bind human fH
H44/76 mutant with heterologous fHbp to
vaccines
7,16 28 3 Control bactericidal test strain for antibodies directed at antigens
other than fHbp in variant group 1
WT Cu385 with heterologous PorA VR to vaccines 19,15 1 1 BactericidalteststrainforantibodiesdirectedatfHbpinvariantgroup1
aPorA variable region (VR) type as described Sacchi [43].
bfHbp ID from peptide database at http://pubmlst.org/neisseria/fHbp.
cVariant group as described by Masignani [8].
doi:10.1371/journal.ppat.1002688.t001
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containing R41S mutant fHbp was used to insert a second copy
into the strain with the R41S fHbp gene integrated into the
chromosome. Characteristics of the three mutants used to prepare
NOMV vaccines are summarized in Table 1.
Characterization of vaccine strains
Binding of human fH to the surface of live bacteria was de-
termined by flow cytometric detection of fluorescence, which was
performed as described previously [29]. Bacteria were grown to
mid-exponential phase in Mueller-Hinton broth supplemented
with 0.25% glucose and 0.02 mM cytidine monophosphate N-
acetyl neuraminic acid (CMP-NANA), harvested by centrifuga-
tion, and suspended in blocking buffer (Dulbecco’s PBS containing
1% (w/v) BSA) at approximately 7.5610
8 cfu/ml. Human fH
(10 mg/ml) or, as controls, anti-fHbp mAb (4 mg/ml), or anti-PorA
mAb (1 mg/ml) was incubated with the cells for 30 min at room
temperature. The anti-fHbp mAb was JAR 5 [30] and the anti-
PorA mAb was P1.7 (National Institute for Biological Standards
and Controls, Potters Bar, UK; NIBSC code: 01/514) [31]. To
detect bound human fH, the cells were incubated with affinity
purified goat anti-human fH (2 mg/ml), followed by AlexaFluor
488 rabbit anti-goat IgG H+L (1:500; Invitrogen). To detect
murine mAbs, the cells were incubated with AlexaFluor 488 goat
anti-mouse IgG H+L (1:500; Invitrogen). The preparations were
fixed with 0.5% formaldehyde in PBS buffer, and the bacterial
cells were analyzed by flow cytometry (LSRFortessa, BD
Biosciences).
Production and characterization of NOMV vaccines
NOMV vaccines were prepared from membrane blebs released
into bacterial culture supernatants as previously described [32]. To
test binding of fH or mAbs by ELISA, the NOMV vaccines (2 mg/
ml in PBS) were adsorbed to the wells of a microtiter plate
(Immulon 2HB; Thermo Scientific) by incubation overnight at
4uC. Non-specific binding was blocked with PBS containing 1%
BSA for 1 h at room temperature. Different concentrations of
purified human fH (Complement Technology) were added to the
plate, and were incubated for 2 h at room temperature. After
washing, bound fH was detected with goat anti-human fH (affinity
purified, 1 mg/ml) followed by rabbit anti-goat IgG conjugated to
alkaline phosphatase (Sigma; 1:5,000). Murine mAb binding to the
NOMV vaccines was tested by a similar procedure except that the
mAbs (anti-fHbp mAb JAR 5 or anti-PorA mAb P1.7) were added
instead of fH, and bound mAbs were detected with goat anti-
mouse IgG conjugated to alkaline phosphatase.
We characterized the three NOMV preparations further by
Western blotting to detect fHbp expression, and by SDS-PAGE.
The proteins in the NOMV preparations were separated by SDS-
PAGE (10% acrylamide NuPAGE; Invitrogen) and stained with
Coomassie blue (SimplyBlue; Invitrogen). For the Western blot,
the proteins were transferred to a polyvinylidene fluoride mem-
brane (Immobilon-FL; Millipore) using an XCell II Blot Module
(Invitrogen). The membrane was blocked using PBS (Roche)
containing 1% (w/v) blocking grade nonfat dry milk (Bio-Rad),
and then washed with PBS containing 0.1% Tween-20 (Sigma).
fHbp was detected using anti-fHbp mAb JAR 5 (0.1 mg/ml) and
goat anti-mouse IgG conjugated to IRDye 800CW (Li-Cor
Biosciences). The IRDye was detected at 800-nm wavelength on
an infrared scanner (Odyssey; Li-Cor Biosciences).
Immunogenicity in wild-type mice
Groups of sixteen to twenty female BALB/c mice, aged 5 weeks,
were immunized with one of three NOMV vaccines (fHbp knock-
out (KO); over-expressed wild-type fHbp (OE WT); or over-
expressed R41S mutant fHbp (OE R41S)). As described above, all
three vaccines were prepared from mutants in which the LpxL1
gene had been inactivated to attenuate endotoxin activity [27],
Each NOMV vaccine dose contained 2.5 mg of protein and
600 mg of aluminum hydroxide (Alhydrogel; Brenntag Biosector).
Additional groups of control mice were immunized with 20 mgo f
recombinant fHbp ID 1 (N=10 mice) or aluminum hydroxide
adjuvant alone (N=7 mice). Two doses were given intraperito-
neally at three-week intervals and blood was collected by cardiac
puncture three weeks after the second dose.
Immunogenicity in human fH transgenic mice
Details of the construction and characterization of human fH
transgenic mice have been described [17]. In the present study, the
number of available human fH transgenic BALB/c mice was
limited, in part because we excluded mice with serum human fH
concentrations ,240 mg/ml as measured by a fHbp capture
ELISA [17]. The rationale for exclusion was our previous data
that suggested that the effect of human fH on decreasing fHbp
immunogenicity was greatest in mice with high serum human fH
concentrations (.250 mg/ml, with the typical range of fH con-
centrations in sera from humans being between 200 to 400 mg/
ml [17]). To maximize the sizes of the treatment groups of fH
transgenic mice, we included both male and female animals, ages
2 to 4 months. The 32 available mice were randomized to one of
four vaccine groups using the random number function in
Microsoft Excel. Thirteen animals were assigned to receive the
NOMV vaccine with over-expressed WT fHbp, and 13 animals to
receive the NOMV vaccine with over-expressed R41S mutant
fHbp. The remaining six mice served as controls (three were
immunized with aluminum hydroxide adjuvant alone and three
were immunized with an NOMV vaccine from a fHbp knock-out
mutant).
For the immunogenicity study in human fH transgenic mice,
three doses of NOMV vaccine (2.5 mg of protein per dose) were
given intraperitoneally at three-week intervals. Blood was collected
by cardiac puncture three weeks after the third dose at which time
the animals were euthanized. During the study, five mice were
removed before completing the vaccination schedule (three in the
group immunized with the NOMV vaccine with over-expressed
R41S fHbp, one in the group immunized with the NOMV vaccine
from the fHbp KO, and one in the group immunized with
aluminum hydroxide). These animals either were males injured
from fighting and were euthanized to minimize pain or distress, or
died for other reasons not related to the procedures.
Serology
Sera from individual mice were tested for IgG anti-fHbp an-
tibody titers by ELISA, which was performed as described pre-
viously [33]. Complement-mediated serum bactericidal activity
was measured using washed, exponential growth-phase bacteria
grown to OD620=0.6 in Mueller-Hinton broth supplemented with
0.25% glucose and 0.02 mM CMP-NANA. The group B test
strain, Cu385, expressed fHbp ID 1 that matched the amino acid
sequence of fHbp ID 1 in the vaccines, and had a PorA variable
region (VR) type heterologous to strain H44/76, which was used
to prepare the NOMV vaccines (Table 1). For measuring bac-
tericidal activity, the mouse sera were heated at 56uC for 30 min
to remove endogenous complement activity. The exogenous com-
plement source was human serum from a donor lacking intrinsic
bactericidal activity. To eliminate possible effects of naturally
acquired non-bactericidal IgG antibodies in the human comple-
ment on the bactericidal titers of the mouse sera [34], the human
Human fH and NOMV fHbp Immunogenicity
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protein G column (HiTrap Protein G HP 1 ml; GE Healthcare) as
previously described [17]. The final 40-ml bactericidal reaction
included different dilutions of the mouse sera, 20% (v/v) human
complement and ,10
3 cfu of the test strain. After one hour of
incubation at 37uC in the presence of 5% CO2,1 2ml of the
reaction were plated. Titers were assigned by the interpolated
dilution of test serum that gave 50% survival of the bacteria after
60 min incubation relative to CFU of negative controls at time 0.
Adsorption of serum anti-fHbp antibody was performed using
recombinant fHbp, or recombinant human albumin as a mock
treatment, each coupled separately to CnBr-activated Sepharose
4B (Sigma), which was performed as described [34]. Two serum
pools were prepared from wild-type mice immunized with the
NOMV vaccine with over-expressed WT fHbp and two serum
pools from mice immunized with the NOMV vaccine with over-
expressed R41S mutant fHbp (each pool contained sera from 9 to
10 mice). The pools were diluted 1:5 and each pool was divided
into three aliquots; one aliquot was incubated with the conjugated
fHbp, the second with the conjugated human albumin (mock
control), and the third was retained as a non-adsorbed sample.
After incubation with the conjugated Sepharose overnight at 4uC,
the beads were transferred to disposable columns (Bio-Rad). Three
column washes were collected and concentrated to the original
sample volume by ultrafiltration (Spin-X UF 6, 10K MWCO;
Corning). By ELISA, the fHbp column removed .99% of the
anti-fHbp antibodies (see Results).
Results
Characterization of mutant strains and vaccines
As described in the Methods, we prepared three meningococcal
mutant vaccine strains for preparation of NOMV vaccines: one
strain was a LpxL1 knock-out (KO) mutant with attenuated en-
dotoxin that also had the fHbp gene inactivated (negative control);
a second was an LpxL1 KO mutant engineered to over-express
wild-type (WT) fHbp ID 1; and a third was an LpxL1 KO mutant
with over-expressed fHbp ID 1 containing the R41S substitution
to eliminate fH binding to fHbp (Table 1). As expected, the
mutant strain with over-expressed WT fHbp bound fH (Figure 1,
Panel A). In contrast, binding of fH to the mutant with over-
expressed R41S fHbp was indistinguishable from that of the fHbp
knock-out mutant (Figure 1, Panel A). The control anti-fHbp
mAb JAR 5 showed similar binding to the strains with over-
expressed WT or R41S fHbp, which showed that both of these
mutants had similar levels of fHbp expression (Figure 1, Panel
B). With the fHbp knock-out mutant, there was only background
signal with the anti-fHbp mAb. An additional control anti-PorA
mAb P1.7 bound equally well to all three strains (Figure 1, Panel
C). By flow cytometry, the mutant vaccine strain with over-
expressed wildtype fHbp had about 4-fold greater binding of anti-
fHbp mAbs than that of the parent wild-type H44/76 strain, and
4-fold greater binding of human fH (Supplemental Figure S1,
Panels A and B, respectively).
We prepared NOMV vaccines from membrane blebs released
into broth culture supernatants by each of the three mutant
vaccine strains using methods previously described [32]. By
ELISA, there was similar binding of the control anti-fHbp mAb,
JAR 5, with the NOMV vaccines from the mutants with over-
expressed WT or R41S mutant fHbp, whereas there was only
background binding with the NOMV vaccine from the fHbp
knock-out mutant (Figure 1, Panel E). The NOMV vaccine
from the mutant with WT fHbp bound ,50 fold-more fH than
the NOMV vaccine with mutant R41S fHbp (Figure 1, Panel
D). Further, binding of fH to the NOMV vaccine with mutant
R41S fHbp was indistinguishable from that of the NOMV vaccine
from the fHbp knock-out mutant. The residual fH binding to the
NOMV vaccines prepared from the mutants with over-expressed
Figure 1. Binding of human fH or control mAbs to mutant vaccine strains and NOMV vaccines. The upper panels (A–C) show binding to
live bacteria by indirect immunofluorescence flow cytometry. The lower panels (D–F) show binding to NOMV vaccines by ELISA. A and D, binding of
fH; B and E, binding of anti-fHbp mAb JAR 5; C and F, binding of a control anti-PorA mAb, P1.7. WT, H44/76DLpxL1 bacteria or NOMV vaccine with
over-expressed wild-type fHbp (blue open circles with solid blue line); R41S, H44/76DLpxL1 bacteria or NOMV vaccine with over-expressed R41S
mutant fHbp (open squares with dashed black line); KO, H44/76DLpxL1DfHbp bacteria or corresponding NOMV vaccine with no detectable fHbp
(dotted orange line (Panels A–C) or inverted orange triangles (Panels D–F)). For the flow cytometric analysis, cells with negative binding (fluorescence
background values close to zero) are displayed as bi-exponential or ‘‘logical’’ negative values on the X axis, as described [42].
doi:10.1371/journal.ppat.1002688.g001
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Neisserial surface protein A (NspA), which recently was identified
is a second meningococcal ligand for fH [35]. The NOMV
vaccines from the two mutants with over-expressed WT fHbp or
fHbp knock-out had similar binding with the control anti-PorA
mAb (Figure 1, Panel F). With the NOMV from the third
mutant with fHbp R41S, there was slightly lower binding with the
control anti-PorA mAb (Figure 1, Panel F).
By Western blotting (Figure 2, Panel A), the NOMV vaccine
from the fHbp knock-out strain did not contain detectable fHbp
(lane 3), whereas the NOMV vaccines from the mutants with over-
expressed WT or R41S fHbp contained similar amounts of fHbp
(lanes 4 and 5, respectively). Although not shown in Figure 2, the
amount of over-expressed fHbp in these NOMV vaccines was
approximately 5-fold higher than that of an NOMV vaccine pre-
pared in a previous study from the parent (wild-type) H44/76
strain [20]. The H44/76 strain naturally expressed relatively high
amounts of fHbp [36].
By SDS-PAGE with Coomassie blue staining, the respective
proteinprofilesofthethreeNOMVvaccinesweresimilar(Figure2,
Panel B). The only exception was a band with a mass of ,25 kDa,
which waspresent inthe NOMVfrom the fHbpKOmutant (lane 3)
but not in the two other NOMV vaccines with over-expressed fHbp
(lanes 4 and 5). This band was not identified. Note also, that a
28 kDa protein co-migrated with fHbp since SDS-PAGE the
28 kDa band was present in the of the NOMV vaccine from the
fHbp knock-out mutant (Panel B, lane 3)b u tn o td e t e c t e db y
Western blot (Panel A, lane 3). In previous experiments, a band
resolving in this portion of SDS-PAGE of NOMV preparations
from wild-type and mutant strains of H44/76 with over-expressed
fHbp was identified by mass spectrometry to contain both fHbp and
OpcA [20].
Serum antibody responses of wild-type mice
We immunized wild-type BALB/c mice with two doses of each
of the NOMV vaccines. Control mice received two doses of the
recombinant fHbp ID 1 vaccine adsorbed with aluminum hy-
droxide, or aluminum adjuvant alone. Since mouse fH does not
bind to fHbp [16], the antibody responses provided information
on vaccine immunogenicity in an animal model in which mouse
fH did not bind to fHbp in any of the vaccines. Although three
doses of the vaccines likely would have been more immunogenic
than two doses, we chose to use two doses as a more sensitive
indicator of possible loss of fHbp immunogenicity from the amino
acid substitution introduced to eliminate fH binding.
Both of the NOMV vaccines with over-expressed WT or mu-
tant R41S fHbp elicited higher serum IgG anti-fHbp titers than
mice immunized with the control recombinant WT fHbp vaccine
(P#0.0002, Figure 3, Panel A). However, the mice immunized
with the NOMV vaccine with mutant fHbp had a 2-fold lower
IgG anti-fHbp geometric mean titer (GMT) than the mice im-
munized with the NOMV vaccine with WT fHbp (P=0.001,
Figure 3, Panel A).
Figure 2. Characterization of native outer membrane vesicle
(NOMV) vaccines prepared from H44/76 mutant strains. A,
Western blot probed with an anti-fHbp mAb, JAR 5. Lane 1, molecular
mass standards (Magic Mark; Invitrogen); Lane 2, purified, recombinant
fHbp ID 1 (0.1 mg); Lanes 3 to 5, NOMV (0.25 mg) from H44/76 mutants.
Lane 3, genetic knock-out of fHbp; Lane 4, over-expressed WT fHbp ID
1; Lane 5, over-expressed mutant R41S fHbp. B, SDS-polyacrylamide gel
stained with Coomassie blue. Lane 1, Molecular mass standards
(Kaleidoscope Prestained; Bio-Rad); lanes 2 through 5 contain the same
respective samples as in Panel A except that there is 2 mgo f
recombinant fHbp (Lane 2) or 10 mg of NOMV (Lanes 3–5).
doi:10.1371/journal.ppat.1002688.g002
Figure 3. Serum antibody responses of wild-type mice
immunized with NOMV vaccines. Each symbol represents the
reciprocal serum titer of an individual mouse, and the horizontal line
represents the geometric mean titer. OE WT, OE R41S or KO, NOMV
vaccines with over-expressed wild-type fHbp, R41S mutant fHbp, or
fHbp knock-out, respectively. Alum, aluminum hydroxide adjuvant only.
rfHbp, recombinant fHbp. A, Serum IgG anti-fHbp antibody responses
measured by ELISA (1/GMT of OE WT vs. OE R41S, P=0.001; OE WT or
OE R41S vs. rfHbp, P#0.0002). B, Serum bactericidal antibody responses
against strain Cu385, which has a mismatched PorA type compared to
the vaccine strains and expresses fHbp ID 1 that matches the vaccine
fHbp antigen (1/GMT of OE WT vs. OE R41S, P=0.003).
doi:10.1371/journal.ppat.1002688.g003
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fHbp elicited higher serum bactericidal responses than to the
recombinant fHbp vaccine. The low responses to the recombi-
nant protein may have reflected the use of a suboptimal two-dose
schedule. The mice immunized with the NOMV vaccine with over-
expressed mutant fHbp had a 4-fold lower bactericidal GMT than the
mice immunized with the NOMV vaccine with over-expressed WT
fHbp (P=0.003, Figure 3, Panel B). Serum bactericidal activity was
not detectable in mice immunized with the NOMV vaccine prepared
from the fHbp knock-out mutant (titers ,1:10). The Cu385 strain
used to measure bactericidal activity had an identical fHbp sequence
but a different PorA VR type than the strains used to prepare the
NOMV vaccines (Table 1). Thus, the high bactericidal responses
elicited by the NOMV vaccines containing fHbp suggested that the
target antigen was fHbp.
To determine the contribution of anti-fHbp antibodies to serum
bactericidal activity, we depleted anti-fHbp antibodies in serum
pools from mice vaccinated with the NOMV vaccines with over-
expressed WT or R41S mutant fHbp by adsorption to immobilized
recombinant WT fHbp (see Methods). By ELISA, the fHbp column
removed greater than 99% of the anti-fHbp antibodies, compared
with a negative control (mock) column containing immobilized
human albumin (Figure 4, Panel A). The fHbp adsorption
procedure did not affect significantly the anti-NOMV ELISA titer
using NOMV fromthefHbp KOmutant astheantigenadsorbedto
the wells (Figure 4, Panel B). Depletion of the serum anti-fHbp
antibodies resulted in a nearly 100-fold decrease in bactericidal
titers against strain Cu385 with fHbp from variant group 1
(Figure 4, Panel C). As a control, we tested bactericidal activity
against a second strain, which was susceptible to anti-PorA
bactericidal activity (a mutant of group B strain H44/76 in which
fHbpID28invariantgroup3had beensubstitutedforfHbp ID1in
variant group 1; Table 1) [37]. The adsorption of the serum anti-
fHbp antibody had no effect on the titers against this second strain
(Figure 4, Panel D). Thus, the serum bactericidal antibodies
against strain Cu385 were directed largely against fHbp.
Collectively, the immunogenicity results from the studies in wild-
type mice showed that the NOMV vaccine with over-expressed
mutant fHbp elicited lower serum anti-fHbp responses than the
NOMV vaccine with over-expressed WT fHbp. Thus, in wild-type
mice whose mouse fH did not bind to fHbp in either NOMV
vaccine, the R41S substitution diminished fHbp immunogenicity.
Serum antibody responses of human fH transgenic mice
In humans, fH would be expected to bind to the WT fHbp
vaccine antigen. To investigate the effect of human fH, we mea-
sured the immunogenicity of the NOMV vaccines in human fH
transgenic mice. The respective ranges of the serum human fH
concentrations of the mice in the different vaccine groups, which
were measured in sera obtained before immunization, were similar
Figure 4. Effect of depletion of serum anti-fHbp antibodies on bactericidal activity. A, IgG anti-fHbp antibody as measured by ELISA.
Representative data are from one of the two serum pools from wild-type mice immunized with the NOMV with over-expressed WT fHbp. The serum
pool either was not adsorbed (‘‘none,’’ open triangles with dotted line), or adsorbed on a human albumin column (‘‘mock,’’ filled circles with solid
line), or on an fHbp column (‘‘fHbp,’’ open circles with solid line). The adsorbed serum samples were adjusted to the original volume applied to the
column. B, IgG anti-NOMV antibody measured by ELISA with the NOMV vaccine prepared from fHbp knock-out strain as the antigen in the wells. Data
are from the same serum pool as shown in Panel A. For panels A and B, similar respective data were obtained with each of the other three serum
pools. C, Serum bactericidal antibody responses against strain Cu385, which has a fHbp variant group 1 antigen matched to that of the vaccines and
a mismatched PorA (see Table 1). Two serum pools for each vaccine group were assayed (NOMV with over-expressed WT fHbp (‘‘OE WT’’) or R41S
mutant fHbp (‘‘OE R41S’’) following depletion on mock or fHbp columns. D. Serum bactericidal antibody titers measured against an isogenic mutant
of strain H44/76 with matched PorA to that of the vaccine strains and a mismatched fHbp in variant group 3. The respective serum pools were the
same as in Panel C.
doi:10.1371/journal.ppat.1002688.g004
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tributions of the groups.
We immunized the transgenic mice with three doses of each of
the NOMV vaccines. The group immunized with the NOMV vac-
cine with over-expressed mutant R41S fHbp had a 5-fold higher
serum IgG anti-fHbp GMT (P=0.002), and a 19-fold higher
serum bactericidal GMT (P=0.001), than the group immunized
with the NOMV vaccine with over-expressed WT fHbp
(Figure 6, Panels A and B, respectively). There was no
correlation between the magnitude of the serum concentrations of
human fH in the individual animals and the serum bactericidal
titers (r=0.15, P=0.62). Thus, in human fH transgenic mice,
there was superior immunogenicity of the NOMV vaccine with
the R41S mutant fHbp, which was opposite to the results obtained
in the wild-type mice.
Discussion
In previous studies in wild-type mice, NOMV vaccines
prepared from mutant meningococcal strains with attenuated en-
dotoxin and over-expressed fHbp elicited broader serum bacteri-
cidal antibody responses than recombinant fHbp vaccines [18,
20,21,23]. The higher activity was particularly evident against
strains with lower fHbp expression [18]. Although there are
conflicting data [38], by adsorption most of the serum bactericidal
antibody elicited by the NOMV vaccines against test strains with
heterologous PorA VR sequence types was directed at fHbp
[20,21,23,28]. The underlying mechanism for the broader anti-
fHbp bactericidal activity is unknown although one study sug-
gested that the IgG anti-fHbp antibodies elicited by the NOMV
vaccine had greater ability to inhibit binding of fH to fHbp than
antibodies elicited by a recombinant fHbp vaccine [18]. These
results suggested that the serum anti-fHbp antibody repertoire to
the NOMV vaccine better targeted the fH-binding surface, as
compared with other sites on the fHbp molecule when recom-
binant fHbp vaccines were used [18].
In the present study, we investigated the immunogenicity of
NOMV vaccines prepared from mutants with over-expressed WT
fHbp that bound human fH, or over-expressed R41S mutant fHbp
that did not bind human fH. Introduction of the R41S mutation
resulted in decreased fHbp immunogenicity in wild-type mice
whose mouse fH did not bind to fHbp (Figure 3). In contrast, the
NOMV vaccine with the mutant fHbp, which did not bind human
fH, elicited nearly 20-fold higher serum bactericidal antibody
responses than the control NOMV with wild-type fHbp that
bound fH (Figure 6). Thus, the modest loss of fHbp immuno-
genicity, which was evident in the WT mice whose mouse fH did
not bind to either vaccine was more than compensated for in the
transgenic mice by the larger effect of human fH on decreasing
immunogenicity of the NOMV vaccine containing fHbp that
bound human fH. These results extend our earlier findings in
human fH transgenic mice, which demonstrated an adverse effect
of human fH on immunogenicity of a recombinant fHbp vaccine
that bound human fH [17]. In the present study we found an even
larger effect of human fH on lowering immunogenicity of the
NOMV vaccine with the wild-type fHbp but, in contrast to our
earlier study [17], we did not find a significant correlation between
immunogenicity and serum human fH levels. The greater effect of
human fH on lowering immunogenicity in the present study, and
the lack of an inverse correlation with the serum human fH levels,
may be explained by our exclusion of transgenic mice with low
serum concentrations of human fH (,240 mg/ml), which was not
done in our previous study.
Two lines of evidence indicated that the serum bactericidal
activity measured in the present study against strain Cu385 was
directed against fHbp. First, this strain was resistant to serum
bactericidal antibodies elicited by the control NOMV vaccine
from the fHbp knock-out strain (Figure 3, Panel B). Second,
depletion of anti-fHbp antibodies from serum pools from wild-type
mice immunized with NOMV vaccines that contained WT or
R41S mutant fHbp resulted in $98% loss of bactericidal activity
(Figure 4, Panel C). Similar adsorption studies were not feasible
with the sera from the human fH transgenic mice because of
insufficient volumes from the fewer animals in each vaccine group
than used in the studies of the WT mice. We expect, however, that
Figure 5. Concentrations of human fH in serum samples obtained before immunization of transgenic mice with NOMV vaccines. OE
WT, mice assigned to group immunized with NOMV with over-expressed wild-type fHbp; OE R41S, mice assigned to group immunized with NOMV
with over-expressed mutant R41S fHbp; KO, control mice that were immunized with NOMV from the fHbp knock-out; Alum, control mice that were
immunized with aluminum hydroxide adjuvant only. Human fH concentrations of mice that were removed from the study before completion of
vaccination are represented as gray filled symbols.
doi:10.1371/journal.ppat.1002688.g005
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strain Cu385 also depended on the presence of antibodies to fHbp.
The recombinant R41S mutant fHbp vaccine used in our
previous study was slightly less immunogenic in wild-type mice
than the recombinant WT fHbp vaccine, although the difference
was not statistically significant [17]. In the present study, we
immunized larger groups of wild-type mice and detected
statistically significant 2-fold lower IgG anti-fHbp titers and 4-
fold lower bactericidal titers elicited by the NOMV vaccine with
over-expressed R41S mutant fHbp, compared with NOMV vac-
cine with WT fHbp. Thus, substitution of serine for arginine at
residue 41 in fHbp ID 1, which resulted in no detectable binding
of human fH, had an adverse effect on fHbp immunogenicity in
mice lacking human fH. Potentially, alternative mutant fHbp
molecules can be identified that eliminate fH binding without this
loss of immunogenicity and that these vaccines will be even more
effective than the R41S mutant fHbp vaccine.
Vaccines containing fHbp molecules that bind human fH are
reported to elicit serum bactericidal antibodies in infants and adults
and, therefore, are likely to confer protection against disease [10,11].
Next-generation, recombinant chimeric fHbp molecules, which
combine domains or regions from different variants, offer the
prospect of extending protection against strains with fHbp from
different variant groups [39,40]. NOMV vaccines from mutant
strains with over-expressed fHbp also can be used to increasebreadth
of protection [19,21]. The present and previously published data
from studies in human fH transgenic mice [17] indicate that the
immunogenicity of fHbp antigens in humansalso can be improved by
incorporating mutations that decrease or eliminate fH binding.
Finally, a number of other pathogenic microbes including N.
gonorrhoeae, Borrelia burgdorferi, Francisella tularensis, Haemophilus influ-
enzae, Streptococcus pneumoniae, S. pyogenes and Yersinia enterocolitica are
reported to bind complement factor H to their surface (Reviewed in
[41]). Although the amino acid sequences of the fH ligands of these
pathogens are not homologous to fHbp, genetic approaches similar
to those employed in the present study could be employed to
eliminate fH binding of these antigens and potentially increase their
immunogenicity in humans. The results of testiing fHbp immuno-
genicity in human fH transgenic mice highlight the potential value
of this mouse model for testing immunogenicity of these vaccines.
Supporting Information
Figure S1 Binding of anti-fHbp mAb and human fH to
live bacteria of N. meningitidis strains as measured by
flow cytometry. Panel A. Binding of anti-fHbp mAbs (JAR 4
and JAR 5; 2 mg/ml of each). Panel B, Binding of human fH
(2 mg/ml). Symbols for H44/76 strains: Wild-type strain (solid red
line), which naturally expresses high amounts of fHbp; LpxL1
knockout mutant vaccine strain with over-expressed wild-type
fHbp (blue line); LpxL1 knockout mutant vaccine strain with fHbp
knocked-out (solid green). In this experiment the LpxL1 knockout
mutant vaccine strain with over-expressed R41S mutant fHbp was
not tested (For results with this strain, see Figure 1).
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